ArticleBMC microbiology2019
Evolution of resistance mechanisms and biological characteristics of rifampicin-resistant Staphylococcus aureus strains selected in vitro.
Article in BMC microbiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 48 citations in OpenAlex.
- Constrained RNA polymerase mutational pathways distinguish corallopyronin A resistance from rifampicin resistance in staphylococci.Scientific reports · 2026Article
- Overexpression of Escherichia coli yaiX Confers Multidrug Resistance and Enhances Virulence in the Silkworm Infection Model.Microbiology and immunology · 2026Article
- CAMPER: mechanistic artificial intelligence for designing peptides that target MRSA persisters.Nature communications · 2026Article
- Effectiveness of clindamycin-based exposure strategies in experimental mature staphylococcal biofilms.Microbiology spectrum · 2025Article
- RpoB H481Y Rifampicin Resistance Mutation-Associated Oxidative Stress Sensitivity Reduces the Virulence of Staphylococcus aureus.Microbiology and immunology · 2025Article
- In Vitro Biological Evaluation of an Alginate-Based Hydrogel Loaded with Rifampicin for Wound Care.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Synergistic combination of baicalein and rifampicin againstFrontiers in microbiology · 2024Article
- Single-cell patterning and characterisation of antibiotic persistent bacteria using bio-sCAPA.Lab on a chip · 2023Article
- Early Staphylococcal Periprosthetic Joint Infection (PJI) Treated with Debridement, Antibiotics, and Implant Retention (DAIR): Inferior Outcomes in Patients with Staphylococci Resistant to Rifampicin.Antibiotics (Basel, Switzerland) · 2023Article
- Incidence of Rifampicin Resistance in Periprosthetic Joint Infection: A Single-Centre Cohort Study on 238 Patients.Antibiotics (Basel, Switzerland) · 2023Article
- Antimicrobial Susceptibility of Staphylococcus aureus Strains and Effect of Phloretin on Biofilm Formation.Current microbiology · 2023Article
- Recurrent spontaneousJAC-antimicrobial resistance · 2023Article
- Revisiting ESKAPE Pathogens: virulence, resistance, and combating strategies focusing on quorum sensing.Frontiers in cellular and infection microbiology · 2023Review
- Combinatorial efficacy of Manuka honey and antibiotics in theFrontiers in cellular and infection microbiology · 2023Article
- Activity of Exebacase (CF-301) against Biofilms Formed by Staphylococcus epidermidis Strains Isolated from Prosthetic Joint Infections.Antimicrobial agents and chemotherapy · 2022Article
- Risk Factors of Recurrent Infection in Patients with Staphylococcus aureus Bacteremia: a Competing Risk Analysis.Antimicrobial agents and chemotherapy · 2022Article
- Antimicrobial Resistance and Transconjugants Characteristics ofAnimals : an open access journal from MDPI · 2022Article
- Molecular Characterization of Rifampicin-ResistantAntibiotics (Basel, Switzerland) · 2021Article
- Novel tigecycline resistance mechanisms inEmerging microbes & infections · 2021Article
- Effect of silver nanoparticles on vancomycin resistant Staphylococcus aureus infection in critically ill patients.Pathogens and global health · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWe aimed to determine the evolutionary pathways of rifampicin resistance in Staphylococcus aureus, and the impact of resistance mutations in the rpoB gene on fitness.
methodsThree clinical strains and one reference strain were used to select for rifampicin-resistant S. aureus variants. The mutations responsible for rifampicin resistance in all of the selected isolates in vitro were investigated by polymerase chain reaction (PCR) and DNA sequencing. To compare the fitness cost of rpoB mutations against their corresponding original isolates, we performed bacterial growth curve assays, static biofilm assays, in vitro competition experiments and an infection model of Galleria mellonella larvae.
resultsWe obtained four rifampicin-resistant S. aureus isolates that showed high levels of resistance to rifampicin with a minimal inhibitory concentration (MIC) of 128 mg/L, and all isolates had a mutation at position 481 (H481F/Y) in RpoB. A broth microdilution assay indicated that mutation of H481F/Y did not affect susceptibility to common antibacterial drugs but slightly increased the vancomycin MIC. To identify the pathways involved in the development of rifampicin resistance, 32 variants (eight mutants for each strain) and four original isolates were selected for gene sequencing. Different generations of isolates were found to harbor various mutations sites. Compared with the corresponding original isolates, an in vitro fitness assay of the variant isolates showed that growth and virulence were reduced, with a statistically significantly decreased fitness, whereas the capacity for biofilm formation was elevated.
conclusionsOur findings suggested that the acquisition of rifampicin resistance in S. aureus was dynamic and was associated with a significant fitness cost.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.